The Effects of Doxorubicin Loaded Aptamer S3-Linked DNA Tetrahedrons on Nasopharyngeal Carcinoma
*Corresponding Author:Received Date: Feb 28, 2025 / Published Date: Mar 30, 2025
Citation: Beatrice G (2025) The Effects of Doxorubicin Loaded Aptamer S3-Linked DNA Tetrahedrons on Nasopharyngeal Carcinoma. Otolaryngol (Sunnyvale) 15: 632.DOI: 10.4172/2161-119X.1000632
Copyright: © 2025 Beatrice G. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Nasopharyngeal carcinoma (NPC) is a malignant tumor that arises in the epithelial cells of the nasopharynx, with high incidence rates in regions of East Asia and Southeast Asia. Despite advances in therapeutic interventions, the prognosis for patients with advanced NPC remains poor due to the limitations of traditional therapies, such as chemotherapy and radiation, which often result in severe side effects. Doxorubicin (DOX) is a widely used chemotherapeutic agent; however, its clinical effectiveness is hindered by its non-specific distribution and associated toxicities. Aptamer-based targeted therapies, including DNA tetrahedrons, have shown promise as a novel and more specific approach to cancer therapy, potentially improving drug delivery and minimizing side effects. This research explores the effects of doxorubicin-loaded aptamer S3-linked DNA tetrahedrons (S3-DT-DOX) on nasopharyngeal carcinoma cells, aiming to enhance the selective cytotoxicity and therapeutic outcomes of NPC treatment. The results demonstrate that the S3-DT-DOX constructs successfully targeted NPC cells, leading to increased cellular uptake, enhanced drug release, and improved therapeutic efficacy compared to free DOX. Furthermore, the S3- DT-DOX platform significantly reduced the side effects associated with traditional chemotherapy. These findings provide compelling evidence for the potential of aptamer-mediated DNA tetrahedron-based drug delivery systems as a promising strategy for the treatment of nasopharyngeal carcinoma.
